over the counter glp 1 agonist oral A GLP-1 Pill May Help You Keep Weight Off After Stopping Wegovy or Zepbound Swapping digestible starches for resistant starch in a meal contributes to a reduction in the blood glucose rise after that meal GLP-1 Supplement for Weight Management

In countries like Denmark, home to Novo Nordisk (Ozempic and Wegovys manufacturer), there are concerns about economic over-reliance on the pharmaceutical sector, to the extent a recent article from the National Public Radio (NPR 2024) has questioned whether Denmark is developing into a pharma state based on the Novo Nordisks chokehold on the Danish economy

Appendix Abbreviations AE(s): Adverse Event(s) BMI Body Mass Index CENTRAL Cochrane Central Register of Controlled Trials CI Confidence Interval CSF Cerebrospinal Fluid GLP-1 Glucagon-Like Peptide-1 GLP-1 RA(s) GLP-1 Receptor Agonist(s) I (Statistical measure of heterogeneity) ICP Intracranial Pressure IIH Idiopathic Intracranial Hypertension IQR Interquartile Ranges logMAR Logarithm of the Minimum Angle of Resolution MD Mean Difference NOS Newcastle-Ottawa Quality Assessment Scale PICO Population, Intervention, Comparison, and Outcomes PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses PROSPERO (International prospective register of systematic reviews Name, not an acronym defined in text) RCT(s) Randomized Controlled Trial(s) RoB2 Revised Cochrane risk-of-bias tool (for randomized trials) RR Risk Ratio SD Standard Deviation SMD Standardized Mean Difference ULN Upper Limit of Normal VRS Verbal Rating Scale WOS/WoS Web of Science Footnotes ORCID iDs: Jamal Ahmad Ahmed Mohamed Hamdy Bahaa Elfakharany Muhammad M

For weight loss specifically, Phase 2 trial data suggests retatrutide produces greater average weight loss (22-24%) compared to tirzepatide (18-22%) at maximum doses

The amount of weight you may lose with Saxenda and any side effects you may have will depend on your individual situation

Meta-analysis of 35 clinical trials demonstrated a modest reduction in LDL cholesterol, total cholesterol, and triglycerides in patients treated with GLP-1 RAs compared to controls (58)